Lu YH, Lu CK, Chen CH, Hsieh YY, et al. Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. PLoS One 2022;17:e0272567.
PMID: 35980912